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Abstract
Background: Although obesity is a well-recognised risk factor for cardiovascular disease (CVD), the impact of long-
term body mass index (BMI) changes in overweight or obese adults, on the risk of heart failure, CVD and mortality
has not been quantified.
Methods: This population-based cohort study used routine UK primary care electronic health data linked to secondary
care and death-registry records. We identified adults who were overweight or obese, free from CVD and who had
repeated BMI measures. Using group-based trajectory modelling, we examined the BMI trajectories of these individuals
and then determined incidence rates of CVD, heart failure and mortality associated with the different trajectories. Cox-
proportional hazards regression determined hazards ratios for incident outcomes.
Results: 264,230 individuals (mean age 49.5 years (SD 12.7) and mean BMI 33.8 kg/m2 (SD 6.1)) were followed-up for a
median duration of 10.9 years. Four BMI trajectories were identified, corresponding at baseline, with World Health
Organisation BMI classifications for overweight, class-1, class-2 and class-3 obesity respectively. In all four groups, there
was a small, stable upwards trajectory in BMI (mean BMI increase of 1.06 kg/m2 (± 3.8)). Compared with overweight
individuals, class-3 obese individuals had hazards ratios (HR) of 3.26 (95% CI 2.98–3.57) for heart failure, HR of 2.72 (2.58–
2.87) for all-cause mortality and HR of 3.31 (2.84–3.86) for CVD-related mortality, after adjusting for baseline
demographic and cardiovascular risk factors.
Conclusion: The majority of adults who are overweight or obese retain their degree of overweight or obesity over the
long term. Individuals with stable severe obesity experience the worst heart failure, CVD and mortality outcomes. These
findings highlight the high cardiovascular toll exacted by continuing failure to tackle obesity.
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Background
Obesity and overweight increase the risk of cardiovascular
disease [1] and heart failure [2], and are important causes
of morbidity and mortality globally. In 2016, an estimated
1.9 billion adults globally were overweight, of which 650
million were obese [3]. In recent UK estimates from the
Health Survey of England [4], 27% of adults were obese,
and the proportion of overweight and obese adults in-
creased from 53% in 1993 to 63% in 2017 [4].
A meta-analysis has shown that for every 5-unit in-
crease in BMI, there is a 29% increase in the risk of cor-
onary heart disease (CHD) which drops to 16% after
adjustment for blood pressure and cholesterol levels [5].
Long-term weight loss in obese individuals through self-
guided efforts or behavioural interventions is not always
sustained. Most behavioural interventions in obese indi-
viduals achieve only modest weight loss ranging from
only − 0.3 to − 3.1 kg at 12 months to − 0.3 to + 1.3 kg
weight gain at 24 months [6], and many severely obese
individuals remain severely obese for at least 5 years [7].
It is thought that a multi-disciplinary approach and
intervention is required to prevent obesity, reduce pro-
gression to more severe forms and lead to substantive
and sustainable public health outcomes [8]. While
weight loss interventions may improve cardiovascular
risk factors [9], metabolic function [10] or even reverse
type 2 diabetes [11], it is unclear what the long term ef-
fect of weight changes are on cardiovascular endpoints.
Few studies have explored how BMI in overweight or
obese individuals may change over time, and any cardio-
vascular impact this may have. No existing research on
BMI trajectories over time [12–16] has focused entirely
on obese and overweight adult populations, so the BMI
course of these individuals is unknown. This aim of this
study was firstly to examine BMI trajectories in the gen-
eral population of adults who were overweight or obese
adults; and secondly to explore the risk of heart failure,
cardiovascular disease (CVD), CVD-related mortality




We conducted a cohort study using data from the UK
Clinical Practice Research Datalink (CPRD), a nationally
representative database of routinely recorded primary
care electronic health records [17]. General practice is
the first point of contact for non-emergency healthcare
in the UK, and over 98% of the UK population are regis-
tered with a General Practitioner. The CPRD database
contains anonymised longitudinal data entered during
routine consultations from general practices who have
agreed to provide patient data. The database has a cover-
age rate of approximately 15% of the UK population and
patients are broadly representative of the UK general
population in terms of age, sex and ethnicity [17]. Pa-
tient records were available from 790 general practices
which contributed to the database during the study
period from 1999 to 2018. Primary care records from
CPRD were linked with secondary care records (Hospital
Episode Statistics) and death registration records from
the Office of National Statistics (ONS). Data access and
ethical approval was granted by the CPRD Independent
Scientific Advisory Committee (Protocol number 18_
195) in August 2018.
Study participants and covariates
We identified individuals aged 18 years or older, with a
recorded or computed BMI (weight divided by the
square of height) of 25 kg/m2 or greater, and subsequent
records of BMI during the study period. Each individual
could have up to five BMI data points – the first re-
corded overweight or obese BMI was defined as the
baseline BMI, and then subsequent BMI measures at 2
years (±90 days), 5 years (±6 months), 8 years (±6
months) and 10 years (±12 months). To be included in
the study, participants had to be registered with the gen-
eral practice for at least one year before the date of their
baseline BMI. Individuals with pre-existing records of
CVD (defined as coronary heart disease, peripheral vas-
cular disease, stroke or transient ischaemic attack) or
heart failure, were excluded from the study. All partici-
pants were followed up until diagnosis of CVD, heart
failure, death, transfer out of the practice or last date of
data collection, whichever occurred first. To ensure that
there were sufficient BMI records for the trajectory ana-
lyses, we included only individuals who had BMI records
at baseline and at least one other defined time point,
prior to the incidence of CVD, heart failure or death.
In all study participants, we collected data on covariates
such as patient demographics (age, sex, ethnicity and so-
cioeconomic status) as well as comorbidities that could
alter their risk of developing CVD or heart failure [18].
Our measure of material socioeconomic deprivation was
the 2015 English index of multiple deprivation (IMD) in
quintiles [19], and this was available for individuals with
linked secondary-care records. Records of comorbidities
collected at baseline were type-2 diabetes, atrial fibrilla-
tion, chronic kidney disease, hypertension, rheumatoid
arthritis and other inflammatory diseases. Smoking status
and records of alcohol consumption were collected at
baseline as well as at the 2-year, 5-year, 8-year and 10-year
follow-up time points.
Outcome ascertainment
Incident CVD was defined as any new clinical diagnosis
of coronary heart disease, stroke, transient ischaemic at-
tack (TIA) or peripheral vascular disease. CVD, heart
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failure and death records were identified from individ-
uals’ primary care, secondary care and ONS death regis-
try records during the study period. Disease codes used
for identification of CVD and heart failure are shown in
the supplementary online file.
Analyses
Analyses were conducted using Stata SE version 15.
Baseline descriptive statistics were presented for the en-
tire study population, including missing data. Although
the inclusion criteria ensured that individuals had a
minimum of 2 BMI records (BMI at baseline and a mini-
mum of one other BMI record), all values of BMI that
were missing at the study set time points and before the
incidence of CVD, heart failure or death, were estimated
using multiple imputation by chained equations proced-
ure. This approach provides estimates for missing values
when data are assumed to be missing at random [20]. It
is also the recommended approach for handing missing
weight data in epidemiological studies using primary
care health records [21], where the practical analytical
approach is to include in the imputation model, vari-
ables that are predictive of the missing data [22]. Previ-
ous research has shown that the use of multiple
imputation for missing weight records in primary care
databases provided results comparable with population
surveys [23]. Baseline BMI, demographic variables such
as age and sex, clinical comorbidities (cardiovascular dis-
ease, diabetes, hypertension, rheumatoid arthritis and
other inflammatory conditions, chronic kidney disease
and atrial fibrillation), smoking status and alcohol con-
sumption were included in the imputation models to
create 10 imputed datasets. Body mass index measures
at baseline, 2 years, 5 years, 8 years and 10 years were
used to assign individuals into trajectories of BMI using
group based trajectory modelling (GBTM). GBTM pro-
vides a statistical method to identify distinctive clusters
of individuals who follow a similar developmental trajec-
tory and enables profiling of the characteristics of indi-
viduals within the clusters [24]. In the GBTM models,
BMI was the dependent variable and time (baseline, 2, 5,
8 and 10 year time-points) was the independent variable.
Models took account of the effect of time-varying covar-
iates: age, smoking status and alcohol consumption on
individuals’ probability of group membership, and
assigned individuals to the group to which they had the
highest probability. The Stata plug-in program (Traj)
was used to estimate group-based trajectory models
using the maximum likelihood estimation method [25].
Data was modelled using the censored normal distribu-
tion and BMI values that were considered clinically im-
plausible (BMI less than 10 kg/m2 or greater than 131
kg/m2) were excluded from analyses. The Bayesian infor-
mation criterion (BIC) was used as criterion for selection
of the best-fitting trajectory model whereby models with
the lower value of BIC was preferred. BIC captures gen-
eralised trends over time while also minimising the risk
of over-fitting the models. While the Akaike’s informa-
tion criterion (AIC) and BIC both aim at achieving a
compromise between model goodness of fit and model
complexity, with maximum likelihood estimates driven
to penalise free parameters, BIC are more stringent than
AIC [26] and is asymptotically consistent, in that it will
select the true model if, among other assumptions, the
true model is among the candidate models considered
[27]. Similar to GBTM methods employed in a previous
study [28], we identified the ideal number of trajectory
groups for our study population, by estimating the BIC
in 2- group models, 3-group models and 4-group
models. This was followed by testing zero-order, linear,
quadratic and cubic specifications for the different tra-
jectory shapes until the best fitting shape was derived. In
selecting the final model, we ensured each trajectory
group had a minimum of 5% of the study population.
The 4-group model with four cubic trajectories was se-
lected as the model with the best-fit due to the low BIC
value as well as having an adequate proportion of the
study population per trajectory group (BIC data are
shown in supplementary Table 1).
Socio-demographic characteristics, clinical profile, co-
morbidities as well as CVD, heart failure and mortality
outcomes were assessed for individuals in the trajectory
groups. Baseline characteristics of individuals between
BMI trajectory groups were compared using the
ANOVA test for continuous variables or the chi-test
for categorical variables. We used survival analyses to
estimate the incidence rates of outcomes for individuals
in the different trajectory groups. The proportional haz-
ards assumption was checked using statistical tests
(Schoenfeld residuals). Multivariate Cox proportional
hazards modelling was used to derive hazards ratios for
CVD, heart failure and mortality in the groups, adjust-
ing for demographic and clinical covariates that were
significantly associated with the exposure and outcome.
The lowest BMI trajectory group, the overweight trajec-
tory group, was the reference for comparison because it
was the largest and most normative group. We then es-
timated the mean change in BMI over the 10 year
period, in the subgroup of individuals who had BMI
data at 10 years. To assess the validity of our assump-
tion that missing data were missing at random, a sensi-
tivity analyses was done using complete case analyses.
Owing to the possibility that not all CVD events are
captured are recorded in primary care records, further
sensitivity analyses was restricted to only individuals
whose primary care records were linked with secondary
care (hospital episode statistics) and the ONS (for mor-
tality records).
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Results
Study population
A total of 264,230 overweight and obese individuals were in-
cluded in the study. The flowchart in Fig. 1 demonstrates
how the study population were derived from the overall
CPRD population of obese and overweight subjects.
Baseline characteristics of the study subjects are shown
in Table 1. Females comprised 62% of individuals in the
study, the mean age at baseline was 42.5 (SD 12.7) years
and the mean BMI was 33.8 (SD 6.1) kg/m2. Linkage
with hospital and death registration data was available
for 138,755 (52.5%) individuals in CPRD. There were
complete BMI records at all 5 set time points for 17.3%
of the study population. 20% of subjects had 4 BMI re-
cords and 30% had 3 BMI records. Multiple imputation
was used to estimate missing BMI values to ensure BMI
records were available at all set times prior to the inci-
dence of CVD, heart failure or death. Ethnicity records
were available for 69.2% of the study population, with
the majority of individuals being white (63.7%). The
most prevalent comorbidities at baseline were hyperten-
sion (19.9%) and type 2 diabetes (8.6%).
In the study population of 264,230 overweight or
obese adults, we identified four distinct BMI trajectories
over time, with a statistically significant difference in the
BMI at baseline for individuals in the different trajector-
ies (p < 0.001). The estimates for posterior probability of
group membership are shown in Supplementary Table 2.
Across the trajectory groups, the average posterior prob-
ability was greater than 0.93, which is above the recom-
mended minimum average probability of 0.70, and the
odds of correct classification for the BMI GBTM groups
were above 30 for all groups, indicating good accuracy
of model assignment (Supplementary Table 2).
The mean BMI at baseline, for individuals in trajectory
group 1 (n = 95,944, 36.3%) was 28.7 kg/m2, correspond-
ing to the WHO overweight BMI category. Individuals
in trajectory group 2 (n = 104,616, 39.6%) had a mean
baseline BMI of 33.7 kg/m2 corresponding to WHO class
1 obesity category. The mean baseline BMI in trajectory
group 3 (n = 50,866, 19.3%) was 39.9 kg/m2 correspond-
ing to WHO class 2 obesity while those in trajectory
group 4 (n = 12,804, 4.9%) had a mean baseline BMI of
49.1 kg/m2 corresponding to WHO class 3 obesity. Al-
though BMI remained relatively stable across the 4 tra-
jectory groups, individuals had a mean BMI increase of
1.06 kg/m2 (± 3.8) over 10 years (Fig. 2).
The characteristics of individuals belonging to the dif-
ferent BMI trajectory groups are shown in Table 2.
Compared to other trajectory groups, the obese class 3-
stable trajectory group comprised of the highest propor-
tion of females. There were greater levels of deprivation
among particularly the most severely obese trajectory
groups. There was also an increasing trend in the preva-
lence of clinical morbidities such as hypertension, atrial
fibrillation, chronic kidney disease and type 2 diabetes,
with increasing severity of obesity, such that individuals
in the overweight-stable trajectory group had the lowest
prevalence whereas those in obese class 3-stable trajec-
tory group had the highest prevalence of comorbidities
at baseline.
Cardiovascular disease, heart failure and mortality
outcomes
There were a total of 30,400 incident cases of cardiovas-
cular disease over 2,829,075 person-years of follow-up
(median follow-up of 10.9 years (IQR 7.0–14.1)). Table 3
shows the overall CVD incidence rates as well as
Fig. 1 Flow chart showing how the study population of overweight and obese subjects were derived
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Age in years (mean (SD)) 49.5 (12.7) 51.2 (11.7) 48.5 (13.2)
Body mass index (kg/m2) 33.8 (6.1) 33.2 (5.4) 34.2 (6.4)
Ethnicity
White 168,330 (63.7) 62,873 (63.1) 105,457 (64.1)
Black African 2154 (0.8) 548 (0.6) 1606 (1.0)
Black Caribbean 2059 (0.8) 495 (0.5) 1564 (1.0)
Black other 595 (0.2) 146 (0.2) 449 (0.3)
Bangladeshi 334 (0.1) 98 (0.1) 236 (0.1)
Chinese 158 (0.1) 56 (0.1) 102 (0.1)
Indian 2908 (1.1) 1032 (1.0) 1876 (1.1)
Pakistani 1852 (0.7) 603 (0.6) 1249 (0.8)
Mixed 595 (0.2) 170 (0.2) 425 (0.3)
Other Asian 1306 (0.5) 518 (0.5) 788 (0.5)
Other (unspecified) 2498 (1.0) 920 (0.9) 1578 (1.0)
Missing ethnicity records 81,441 (30.8) 32,131 (32.3) 49,310 (30.0)
IMD quintile
1 (least deprived) 25,534 (9.7) 10,186 (10.2) 15,348 (9.3)
2 29,958 (11.3) 11,404 (11.5) 18,554 (11.3)
3 28,070 (10.6) 10,260 (10.3) 17,810 (10.8)
4 30,167 (11.4) 10,697(10.7) 19,470 (11.8)
5 (most deprived) 24,911 (9.4) 8517 (8.6) 16,394 (10.0)
Missing records 125,590 (47.5) 48,526 (48.7) 77,064 (46.8)
Smoking status
Ex-smoker 78,539 (29.7) 37,187 (37.3) 41,352 (25.1)
Light smoker (1–9 cigs/day) 18,053 (6.8) 7209 (7.2) 10,844 (6.6)
Moderate smoker (10–19/day) 13,182 (5.0) 4173 (4.2) 9009 (5.5)
Heavy smoker (20–39/day) 11,213 (4.2) 4622 (4.6) 6591 (4.0)
Non-smoker 142,969 (54.1) 46,289 (46.5) 96,680 (58.7)
Missing 274 (0.1) 110 (0.1) 164 (0.1)
Alcohol consumption
Trivial (< 1 unit/day) 88,408 (33.5) 28,902 (29.0) 59,506 (36.1)
Light (1–2 units/day) 39,423 (14.9) 19,986 (20.1) 19,437 (11.8)
Moderate (3–6 units/day) 22,394 (8.5) 13,231 (13.3) 9163 (5.6)
Heavy (7–9 units/day) 7090 (2.7) 5271 (5.3) 1819 (1.1)
Very heavy (> 9 units/day) 4377 (1.7) 3621 (3.6) 756 (0.5)
Ex-alcohol consumption 9660 (3.7) 4477 (4.5) 5183 (3.2)
No alcohol consumption 84,698 (32.1) 21,433 (21.5) 63,265 (38.4)
Missing 8180 (3.1) 2669 (2.7) 5511 (3.4)
Co-morbidities
Atrial fibrillation 2144 (0.8) 1266 (1.3) 878 (0.5)
Chronic kidney disease 2460 (0.9) 953 (1.0) 1507 (0.9)
Hypertension 52,574 (19.9) 22,203 (22.3) 30,371 (18.4)
Type-2 diabetes 22,844 (8.6) 11,682 (11.7) 11,162 (6.8)
Rheumatoid arthritis /inflammatory diseases 4857 (1.8) 1078 (1.1) 3779 (2.3)
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incidence rates of coronary heart disease (CHD), stroke/
transient ischemic attack (TIA), peripheral vascular dis-
ease, heart failure, and mortality in the trajectory groups.
The incidence rate of CVD in the entire study popula-
tion (per 1000 person-years) was 10.75 (95% CI 10.61–
10.87). The CVD incidence rate (per 1000 person-years)
among individuals in the overweight-stable trajectory
group was 9.30 (9.12–9.49). Higher incidence rates of
overall CVD and CVD subtypes were observed in obese
class 1-stable trajectory group compared to overweight-
stable individuals but no further increase in incidence
rates of CHD, stroke/TIA or peripheral vascular disease,
with more severe categories of obesity from obese class
1-stable to obese class 3-stable groups. There was how-
ever a substantial and significant gradient in heart failure
incidence with increasing severity of obesity from
overweight-stable to obese class 3-stable trajectory
groups, such that heart failure incidence rate (per 1000
person years) in overweight-stable trajectory individuals
was 1.70 (1.6–1.8), and 5.70 (5.3–6.1) in obese class 3-
stable trajectory individuals (score test for trend across
BMI groups p < 0.0001).
A total of 24,022 deaths occurred during the period of
follow-up, of which 2827 (11.8%) were cardiovascular
deaths. The overall mortality rate in the study popula-
tion (per 1000 person-years) was 8.5 (8.4–8.6). All-cause
mortality and CVD-related mortality rates increased
with more severe categories of obesity (shown in Table
3). As well as having the earliest onset of incident CVD,
obese class 3-stable trajectory individuals had the highest
all-cause mortality rate, CVD-related mortality rate and
the youngest age at death.
Table 4 shows the hazards ratios for CVD, heart fail-
ure and mortality outcomes for individuals in obese 1-
stable, obese 2-stable and obese 3-stable trajectory
groups, compared to individuals in the overweight-stable
trajectory group. After adjusting for age, sex and comor-
bidities, individuals in obese class 1, 2 and 3 trajectory
groups had higher risks of all CVD, heart failure and
mortality outcomes, compared to individuals in the
overweight-stable trajectory group. An increase in cor-
onary heart disease (HR 1.14 (95% CI 1.10–1.18)) and
stroke/TIA risk (HR 1.09 (1.03–1.15)) was observed in
obese class 1-stable compared to overweight individuals
but no further increase in risk of these conditions were
found with more severe categories of obesity. In the
most severely obese (obese 3-stable) group, there was no
statistically significant difference in the risk of coronary
heart disease (HR 1.06 (0.99–1.16)) and stroke (HR 1.04
(0.92–1.18)), compared to individuals in the overweight-
stable group. The risk of peripheral vascular disease did
not differ significantly between those in the overweight,
obese 1-stable and obese 2-stable trajectory groups.
There was however, a reduced risk of peripheral vascular
disease risk in obese 3-stable adults compared to those
in the overweight-stable group (HR 0.73 (0.60–0.89)).
Fig. 2 Body mass index (BMI) trajectories using BMI measures at baseline and then follow-up at 2 years, 5 years, 8 years and 10 years. Percentages
below plot represent percentage of study population within each trajectory group. Mean BMI change in trajectory group 1 (overweight-stable
group): + 0.99 (SD 3.10) kg/m2 . Mean BMI change in trajectory group 2 (obese class 1-stable group): + 1.19 (SD 1.67) kg/m2. Mean BMI change in
trajectory group 3 (obese class 2-stable group): + 1.04 (SD 4.59) kg/m2 Mean BMI change in trajectory group 4 (obese class 3-stable group): + 0.62
(SD 6.27) kg/m2
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Table 2 Sociodemographic and clinical characteristics by BMI trajectory groups (N = 264,230)
Trajectory 1
(overweight-S) (n = 95,944)
Trajectory 2







Patient characteristics (Sociodemographic characteristics)
Age at start of study (mean (SD)) 49.5 (13.2) 49.9 (12.7) 49.1 (12.2) 48.8 (11.2)
Male gender n (%) 37,882 (39.5) 41,685 (39.9) 16,652 (32.7) 3371 (26.3)
Smoking
Ex-smoker 27,950 (29.1) 31,763 (30.4) 15,123 (29.7) 3703 (28.9)
Light smoker (1–9 cigs/day) 6918 (7.2) 7071 (6.8) 3270 (6.4) 794 (6.2)
Moderate smoker (10–19 cigs/day) 5118 (5.3) 5214 (5.0) 2347 (4.6) 503 (3.9)
Heavy smoker (20–39 cigs/day) 3827 (4.0) 4470 (4.3) 2297 (4.5) 619 (4.8)
Non-smoker 52,070 (54.3) 55,989 (53.5) 27,757 (54.6) 7153 (55.9)
Missing 61 (0.1) 109 (0.1) 72 (0.1) 32 (0.3)
Alcohol consumption
Trivial (< 1 unit/day) 31,978 (33.3) 35,035 (33.5) 17,192 (33.8) 4203 (32.8)
Light (1–2 units/day) 16,405 (17.1) 15,773 (15.1) 6133 (12.1) 1112 (8.7)
Moderate (3–6 units/day) 9746 (10.2) 8748 (8.4) 3314 (6.5) 586 (4.6)
Heavy (7–9 units/day) 2883 (3.0) 2961 (2.8) 1076 (2.1) 170 (1.3)
Very heavy (> 9 units/day) 1621 (1.7) 1905 (1.8) 722 (1.4) 129 (1.0)
Ex-alcohol consumption 3086 (3.2) 3759 (3.6) 2174 (4.3) 641 (5.0)
No alcohol consumption 28,076 (29.3) 33,168 (31.7) 18,113 (35.6) 5341 (41.7)
Missing 2149 (2.2) 3267 (3.1) 2142 (4.2) 622 (4.9)
Deprivation (IMD quintile)
1 (least deprived) 10,122 (10.6) 10,251 (9.8) 4334 (8.5) 827 (6.5)
2 11,043 (11.5) 12,124 (11.6) 5549 (10.9) 1242 (9.7)
3 9644 (10.1) 11,386 (10.9) 5654 (11.1) 1386 (10.8)
4 9889 (10.3) 12,173 (11.6) 6412 (12.6) 1693 (13.2)
5 (most deprived) 7528 (7.9) 9818 (9.4) 5799 (11.4) 1766 (13.8)
Missing records 47,718 (49.7) 48,864 (46.7) 23,118 (45.5) 5890 (46.0)
Weight profile and clinical characteristics
Body mass index in kg/m2 (mean (SD))
Baseline BMI 28.7 (2.2) 33.7 (2.7) 39.9 (3.5) 49.1 (5.7)
BMI at 2 years 28.6 (2.2) 33.7 (2.4) 39.9 (3.2) 49.1 (5.4)
BMI at 5 years 29.2 (2.3) 34.5 (2.4) 40.8 (3.1) 50.0 (5.3)
BMI at 8 years 29.5 (2.5) 34.8 (2.6) 41.1 (3.3) 50.1 (5.4)
BMI at 10 years 29.7 (2.8) 34.9 (3.0) 41.1 (3.7) 49.8 (5.7)
Mean BMI change over 10 years 1.0 (3.1) 1.2 (3.7) 1.0 (4.6) 0.6 (6.3)
Prevalence of comorbidities at baseline
Atrial fibrillation 671 (0.7) 865 (0.8) 452 (0.9) 156 (1.2)
Chronic kidney disease 771 (0.8) 998 (1.0) 532 (1.0) 159 (1.2)
Hypertension 15,708 (16.4) 21,438 (20.5) 12,009 (23.6) 3419 (26.7)
Type-2 diabetes 6384 (6.7) 8930 (8.5) 5609 (11.0) 1921 (15.0)
Rheum arthritis/inflammatory diseases 1674 (1.7) 1970 (1.9) 952 (1.9) 261 (2.0)
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The risk of heart failure, all-cause mortality and CVD-
related mortality increased considerably with increasing
severity of obesity such that after adjusting for age, sex
and comorbidities, individuals in obese class 3-stable tra-
jectory group had hazards ratios of 3.3 for heart failure,
3.3 for CVD-related deaths and 2.7-for all-cause mortal-
ity, compared to individuals in the overweight-stable tra-
jectory group.
Figure 3 illustrates the cumulative outcome-free sur-
vival of individuals in the trajectory groups.
In sensitivity analyses done using only the BMI records
available in patients’ electronic health records (without
multiple imputation of missing BMI records), four BMI
trajectory groups were identified and the BMI measures
across the BMI trajectories were similar to measures in
the main study which used multiple imputation to esti-
mate missing BMI records. Also, similar to findings in the
main study, there was a small stable upwards trajectory
across all 4 groups, with an overall mean BMI increase of
1.26 kg/m2 (SD 4.47) over 10 years (supplementary Table 3
and supplementary Figure 1).
In further sensitivity analyses restricted to 138,755 in-
dividuals whose primary care records were linked with
secondary care and ONS death registration records, the
hazards ratios for overall CVD, coronary heart disease,
stroke/TIA, heart failure, all-cause mortality and CVD-
related death remained significantly higher in obese class
1-stable, class 2-stable and class 3-stable individuals,
compared with the overweight-stable trajectory group of
individuals. As in the main analyses, there was no ob-
served increase in the risk of peripheral vascular disease
in adults who were obese compared to overweight adults
(supplementary Table 4).
Discussion
Main findings of paper
In this large general population cohort study of adults
who were overweight or obese, we observed a stable up-
wards BMI trajectory over time whereby most subjects
retained their degree of obesity over the long term. The
overall risk of CVD, heart failure and mortality increased
with increasing severity of obesity. Whilst there was no
significant increase in risk of coronary heart disease and
stroke in the most severely obese group, the increase in
CVD risk was most marked for heart failure and mortal-
ity. After adjusting for the effect of age, sex and













Cardiovascular disease and heart failure outcomes
Age (years) at first CVD diagnosis (mean (SD)) 65.9 (12.0) 66.2 (11.8) 65.2 (11.8) 64.1 (10.9)
Follow-up (1000 person years) 1100 1100 517.7 123.1
Number of events (%)
Any CVD 10,054 (10.5) 12,666 (12.1) 6137 (12.1) 1543 (12.1)
CHD 6074 (6.3) 7569 (7.2) 3329 (6.5) 714 (5.6)
Stroke/TIA 2675 (2.8) 3152 (3.0) 1436 (2.8) 300 (2.3)
PVD 1246 (1.3) 1425 (1.4) 595 (1.2) 108 (0.8)
Heart failure 1836 (1.9) 3175 (3.0) 1947 (3.8) 702 (5.5)
Incidence rate (95% CI) of CVD and heart failure, per (1000 person-years)
Any CVD 9.30 (9.1–9.5) 11.44 (11.2–11.6) 11.86 (11.6–12.2) 12.54 (11.9–13.2)
Coronary heart disease 5.62 (5.5–5.8) 6.83 (6.7–7.0) 6.43 (6.2–6.7) 5.80 (5.4–6.2)
Stroke/TIA 2.48 (2.4–2.6) 2.85 (2.7–2.90) 2.77 (2.6–2.9) 2.44 (2.2–2.7)
Peripheral vascular disease 1.15 (1.1–1.2) 1.29 (1.2–1.4) 1.15 (1.1–1.2) 0.88 (0.7–1.1)
Heart failure 1.70 (1.6–1.8) 2.87 (2.8–3.0) 3.76 (3.6–3.9) 5.70 (5.3–6.1)
Mortality outcomes
Deaths during follow-up n(%) (total n = 24,022) 7938 (8.3) 9175 (8.8) 5092 (10.0) 1817 (14.2)
Age (years) at death (mean (SD)) 74.5 (12.1) 73.6 (12.0) 70.9 (12.3) 67.3 (11.8)
CVD related death n(%) (total n = 2827) 761 (0.8) 1165 (1.1) 679 (1.3) 222 (1.7)
Mortality rate (95% CI), number of events per 1000 person-years
All-cause mortality rate 7.35 (7.2–7.5) 8.28 (8.1–8.5) 9.84 (9.6–10.1) 14.76 (14.1–15.5)
CVD-related mortality rate 0.70 (0.7–0.8) 1.05 (1.0–1.1) 1.31 (1.2–1.4) 1.80 (1.6–2.1)
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comorbidities, individuals in the most severely obese
group had a 3.3-fold higher risk of heart failure, 3.3 fold
higher risk of CVD-related mortality and 2.7-fold higher
risk of all-cause mortality compared with overweight in-
dividuals. There were greater levels of socioeconomic
deprivation with increasing severity of obesity, confirm-
ing that this is disproportionately an issue in the materi-
ally deprived.
Strengths and limitations
To our knowledge, this is the first and largest study to
analyse overweight and obese adults’ BMI trajectories
and their impact on CVD endpoints, heart failure, and
mortality. We had a large sample size of obese and
overweight individuals who were studied prospectively
with multiple BMI measures per individual over an ex-
tensive follow-up period. Linkage of individuals’ routine
electronic primary care records to their secondary care
and death registration records, enabled more robust ex-
trapolation of CVD diagnosis and mortality data. The
use of health professional-recorded rather than self-
reported BMI measures minimised the risk of inaccur-
acies in the study. By using data from a large nationally
representative database of UK electronic health records,
the study findings can be generalised to the general
population of overweight and obese adults.
Some limitations of this study are recognised. Body
mass index is a surrogate measure of adiposity. Body




Adjusted hazards ratio (95% CI)
CVD outcome Trajectory
group
Model adjusted for age
and sex
Model adjusted for age, sex
and comorbiditiesa
Overall CVD overweight-S 1.00 1.00 1.00
obese 1-S 1.25 (1.22–1.28) 1.24 (1.21–1.28) 1.15 (1.12–1.19)
obese 2-S 1.32 (1.28–1.36) 1.46 (1.41–1.51) 1.27 (1.23–1.31)
obese 3-S 1.42 (1.35–1.50) 1.75 (1.66–1.85) 1.40 (1.33–1.48
Coronary heart disease overweight-S 1.00 1.00 1.00
obese 1-S 1.23 (1.19–1.28) 1.23 (1.18–1.27) 1.14 (1.10–1.18)
obese 2-S 1.17 (1.12–1.22) 1.30 (1.24–1.35) 1.13 (1.09–1.18)
obese 3-S 1.07 (0.99–1.16) 1.31 (1.22–1.42) 1.06 (0.99–1.16)
Stroke/ TIA overweight-S 1.00 1.00 1.00
obese 1-S 1.18 (1.12–1.24) 1.16 (1.10–1.22) 1.09 (1.03–1.15)
obese 2-S 1.16 (1.09–1.24) 1.27 (1.19–1.36) 1.13 (1.06–1.20)
obese 3-S 1.04 (0.93–1.18) 1.26 (1.12–1.42) 1.04 (0.92–1.18)
Peripheral vascular
disease
overweight-S 1.00 1.00 1.00
obese 1-S 1.13 (1.05–1.22) 1.13 (1.04–1.22) 0.99 (0.92–1.07)
obese 2-S 1.02 (0.92–1.12) 1.16 (1.06–1.29) 0.92 (0.83–1.01)
obese 3-S 0.79 (0.65–0.96) 1.03 (0.85–1.25) 0.73 (0.60–0.89)
Heart failure overweight-S 1.00 1.00 1.00
obese 1-S 1.73 (1.63–1.83) 1.73 (1.63–1.83) 1.51 (1.42–1.60)
obese 2-S 2.31 (2.16–2.46) 2.70 (2.53–2.88) 2.09 (1.96–2.23)
obese 3-S 3.58 (3.28–3.91) 4.94 (4.53–5.40) 3.26 (2.98–3.57)
All-cause mortality overweight-S 1.00 1.00 1.00
obese 1-S 1.16 (1.13–1.20) 1.16 (1.12–1.19) 1.12 (1.09–1.16)
obese 2-S 1.41 (1.36–1.46) 1.63 (1.58–1.69) 1.55 (1.50–1.61)
obese 3-S 2.17 (2.06–2.29) 2.96 (2.81–3.12) 2.72 (2.58–2.87)
CVD-related deaths overweight-S 1.00 1.00 1.00
obese 1-S 1.53 (1.40–1.68) 1.54 (1.40–1.68) 1.44 (1.31–1.58)
obese 2-S 1.94 (1.75–2.15) 2.33 (2.10–2.59) 2.06 (1.86–2.29)
obese 3-S 2.73 (2.35–3.17) 3.98 (3.42–4.63) 3.31 (2.84–3.86)
Trajectory group 1 (overweight-stable) used as baseline group for comparison
a Multivariate cox regression models adjusted for age, sex, hypertension, type 2 diabetes, atrial fibrillation and chronic kidney disease
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composition of fat and skeletal muscle mass changes
with age [29] and differs between sexes and ethnic
groups [30]. While other indices such as waist-hip ratio
and waist circumference are more suitable and accurate
measures of adiposity than BMI, these are not used rou-
tinely in clinical practice and are not routinely available
in electronic heath records. Over 60% of our study
population were White, and so the CVD risk profile and
CVD-related outcomes in the study population may not
be directly generalizable to, or may underestimate
obesity-related heart failure, CVD and mortality risk in
other ethnic populations. There was no information on
physical activity level or dietary intake so it remains un-
clear whether weight change observed in individuals’
was intentional or non-intentional and due to pres-
ence of disease. Lastly, a study inclusion criterion was
a minimum of 2 BMI entries in subjects’ primary care
records so there is a small risk of selection bias in
the population studied. We had missing BMI data
and acknowledge that this can constitute considerable
challenges in the analyses and interpretation of results
as well as potentially weaken the validity of results
and conclusion [20]. However, we estimated these
missing BMI records using multiple imputation based
on the missing at random assumption. A sensitivity
analysis examined the effect of this assumption and
found that results of analyses using only available
BMI records were similar to results of analyses using
multiple imputation.
Comparison with existing literature
This is the first study to evaluate the long-term impact
of overweight and obese individuals’ BMI trajectory on
cardiovascular endpoints, heart failure and mortality
outcomes. While the association between obesity and
cardiovascular disease is established [1, 2], our study
sought to assess the effect of long-term BMI changes, ra-
ther than single BMI measures, on the risk of CVD and
related outcomes. We particularly observed a strong sig-
nificant gradient in heart failure risk which increased
with more severe forms of obesity. This provides con-
firmatory evidence of the graded increase in heart failure
risk with increasing obesity. The lack of a clear relation-
ship between degree of obesity and the risk of peripheral
vascular disease, as well as the reduced risk of peripheral
vascular disease in the most severely obese group, is
similar to findings in the Framingham heart study. As
had been previously suggested [31], this unclear relation-
ship may be either due to under-diagnosis of peripheral
vascular disease, or a difference in the underlying disease
mechanism compared to other types of CVD.
In relation solely to obesity, our findings in a large
general adult population expand on those of a smaller
study of 3070 Canadian adults which similarly found no
significant change in individuals’ BMI over time [32].
Similarly, a retrospective cohort study of 11,735 adults
with severe obesity (BMI 35 kg/m2 or greater) in the US,
found that severely obese individuals remained in that
BMI category over at least 5 years [7]. The current study
Fig. 3 Kaplan Meier survival plots showing cumulative outcome-free survival of individuals in the 4 BMI trajectory groups. With increasing BMI
trajectory groups, individuals had higher risks of non-fatal cardiovascular outcomes, heart failure and mortality
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is the largest prospective investigation to assess long
term changes in BMI over time. Our finding that the
general population of adults who were overweight or
obese followed one of four stable upwards BMI trajec-
tories over a decade, elaborates on previous research.
Previous studies of the association between obesity
and mortality have produced conflicting results. In the
original Framingham heart study and the Framingham
offspring study, maximum BMI over a 24 year period
was strongly associated with subsequent all-cause mor-
tality [33]. However a systematic review of the risk of
all-cause mortality in overweight and obese relative to
normal weight individuals in the general population,
found lower risk of mortality in overweight compared to
normal weight subjects, but the highest mortality risk in
more severely obese subjects with class 2 and 3 obesity
[34]. More recently, a population-based cohort study
found a J-shaped association between BMI and overall
mortality such that lower BMI was associated with in-
creased mortality risk, but the absolute mortality burden
was predominantly driven by obesity [35]. In the current
study, we observed a stepwise increase in the risk of all-
cause and CVD-related mortality with increasing severity
of obesity. This persisted after adjusting for the effect of
age, sex, hypertension, type 2 diabetes, atrial fibrillation
and chronic kidney disease. This observed association
may be due to several plausible mechanisms. Severe
obesity is a risk factor for dyslipidaemia and is associated
with devastating health consequences such as obesity
hypoventilation syndrome, obstructive sleep apnoea,
liver disease and certain types of cancers [36], which
could independently or synergistically increase the risk
of mortality.
Some studies have reported an ‘Obesity paradox’ with
clinically better outcomes in overweight and obese pa-
tients compared to normal weight patients in the con-
text of prevalent cardiovascular disease such as heart
failure [37] or following an acute coronary event [38]. In
contrast, in the current study population, free from CVD
at the start of follow-up, individuals with more severe
obesity had earlier onset of incident CVD and earlier age
at death, than overweight individuals. Our study pro-
vides compelling evidence of poor health outcomes asso-
ciated with obesity.
Conclusions
Despite widespread efforts to prevent and manage obes-
ity, the majority of adults who are overweight or obese
in the general population continue to remain so in the
long term. This is associated with a three-fold increase
in heart failure, cardiovascular disease and mortality risk
in the stably severe obese population. This research
highlights the high cardiovascular toll exacted by con-
tinuing failure to tackle obesity, particularly among more
socio-economically deprived populations. More effective
policies and weight-management interventions at soci-
etal, cultural and health service levels are needed to ad-
dress this increasing burden. Further research is also
needed to explore whether interventions to change BMI
trajectories would have an impact on future CVD
outcomes.
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